Analysts’ Weekly Ratings Changes for Opthea (OPT)

Several analysts have recently updated their ratings and price targets for Opthea (NASDAQ: OPT):

• 3/25/2025 – Opthea had its “underperform” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $1.00 price target on the stock, down previously from $8.00.
• 3/25/2025 – Opthea was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating. They now have a $2.00 price target on the stock, down previously from $12.00.
• 3/25/2025 – Opthea was downgraded by analysts at Leerink Partners from an “outperform” rating to a “market perform” rating. They now have a $1.00 price target on the stock, down previously from $12.00.
• 3/24/2025 – Opthea was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating.
• 3/24/2025 – Opthea was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 2/28/2025 – Opthea had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.

Opthea Stock Performance

OPT stock opened at $3.41 on Tuesday. Opthea Limited has a one year low of $1.79 and a one year high of $6.30. The company has a fifty day moving average of $4.27 and a 200-day moving average of $4.08.

Institutional Investors Weigh In On Opthea

Institutional investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC acquired a new stake in shares of Opthea in the 4th quarter valued at approximately $556,000. Jane Street Group LLC purchased a new position in Opthea in the third quarter worth $114,000. Citadel Advisors LLC acquired a new stake in Opthea in the fourth quarter valued at $79,000. Twin Lakes Capital Management LLC purchased a new stake in shares of Opthea during the 3rd quarter worth $81,000. Finally, OLD Mission Capital LLC acquired a new position in shares of Opthea during the 4th quarter worth $42,000. Hedge funds and other institutional investors own 55.95% of the company’s stock.

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.